A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

NCT05128344 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Strategic decision

Conditions

Spasms, Infantile

Interventions

DRUG: AMZ002 injectable solution, 0.5mg/mL
DRUG: Vigabatrin, oral

Sponsor

Amzell